Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark E Fleury

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
JAMA Oncology|January 11, 2019
Association of Patient Comorbid Conditions With Cancer Clinical Trial ParticipationJoseph M Unger, Dawn L Hershman, Mark E Fleury, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 10, 2022
Strategies to Advance Equity in Cancer Clinical TrialsCarmen E Guerra, Mark E Fleury, Leslie P Byatt, et al.
Journal of the National Cancer Institute|March 12, 2019
Systematic Review and Meta-Analysis of the Magnitude of Structural, Clinical, and Physician and Patient Barriers to Cancer Clinical Trial ParticipationJoseph M Unger, Riha Vaidya, Dawn L Hershman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 2, 2024
National Estimates of the Participation of Patients With Cancer in Clinical Research Studies Based on Commission on Cancer Accreditation DataJoseph M Unger, Lawrence N Shulman, Matthew A Facktor, et al.
Cancer|October 18, 2023
Provider motivations and barriers to cancer clinical trial screening, referral, and operations: Findings from a surveyKelly Durden, Patricia Hurley, Dorothy L Butler, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 27, 2005
Synergy between interstitial flow and VEGF directs capillary morphogenesis in vitro through a gradient amplification mechanismCara-Lynn E Helm, Mark E Fleury, Andreas H Zisch, et al.
Journal of Clinical and Translational Science|October 20, 2025
Assessing populations with access to National Cancer Institute-funded sites using local distance-based service areasSharon P Shriver, Liora Sahar, Vanhvilai L Douangchai Wills, et al.
Cancer Cell|June 15, 2007
Autologous chemotaxis as a mechanism of tumor cell homing to lymphatics via interstitial flow and autocrine CCR7 signalingJacqueline D Shields, Mark E Fleury, Carolyn Yong, et al.
Journal of the National Cancer Institute|October 6, 2020
"When Offered to Participate": A Systematic Review and Meta-Analysis of Patient Agreement to Participate in Cancer Clinical TrialsJoseph M Unger, Dawn L Hershman, Cathee Till, et al.
JAMA Network Open|December 9, 2021
Trends in Use of Next-Generation Sequencing in Patients With Solid Tumors by Race and Ethnicity After Implementation of the Medicare National Coverage DeterminationDaniel M Sheinson, William B Wong, Craig S Meyer, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
JAMA Oncology|January 11, 2019
Association of Patient Comorbid Conditions With Cancer Clinical Trial ParticipationJoseph M Unger, Dawn L Hershman, Mark E Fleury, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 10, 2022
Strategies to Advance Equity in Cancer Clinical TrialsCarmen E Guerra, Mark E Fleury, Leslie P Byatt, et al.
Journal of the National Cancer Institute|March 12, 2019
Systematic Review and Meta-Analysis of the Magnitude of Structural, Clinical, and Physician and Patient Barriers to Cancer Clinical Trial ParticipationJoseph M Unger, Riha Vaidya, Dawn L Hershman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 2, 2024
National Estimates of the Participation of Patients With Cancer in Clinical Research Studies Based on Commission on Cancer Accreditation DataJoseph M Unger, Lawrence N Shulman, Matthew A Facktor, et al.
Cancer|October 18, 2023
Provider motivations and barriers to cancer clinical trial screening, referral, and operations: Findings from a surveyKelly Durden, Patricia Hurley, Dorothy L Butler, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 27, 2005
Synergy between interstitial flow and VEGF directs capillary morphogenesis in vitro through a gradient amplification mechanismCara-Lynn E Helm, Mark E Fleury, Andreas H Zisch, et al.
Journal of Clinical and Translational Science|October 20, 2025
Assessing populations with access to National Cancer Institute-funded sites using local distance-based service areasSharon P Shriver, Liora Sahar, Vanhvilai L Douangchai Wills, et al.
Cancer Cell|June 15, 2007
Autologous chemotaxis as a mechanism of tumor cell homing to lymphatics via interstitial flow and autocrine CCR7 signalingJacqueline D Shields, Mark E Fleury, Carolyn Yong, et al.
Journal of the National Cancer Institute|October 6, 2020
"When Offered to Participate": A Systematic Review and Meta-Analysis of Patient Agreement to Participate in Cancer Clinical TrialsJoseph M Unger, Dawn L Hershman, Cathee Till, et al.
JAMA Network Open|December 9, 2021
Trends in Use of Next-Generation Sequencing in Patients With Solid Tumors by Race and Ethnicity After Implementation of the Medicare National Coverage DeterminationDaniel M Sheinson, William B Wong, Craig S Meyer, et al.
Pageof 3